Circulating Tumor DNA in Melanoma Patients

The aim of this prospective clinical study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study evaluates the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.

NCT Number	NCT07422805
Lead Sponsor	Institute of Oncology Ljubljana
Conditions	Melanoma, Skin Cancer
Enrollment	176 participants
Start Date	2021-11-01
Primary Completion	2023-11-30 (estimated)
Study Completion	2026-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-27